3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Small Cell Lung Carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Esophageal Neoplasms
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Pancreatic Adenocarcinoma
1
PD-L1-selected Solid Tumors
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Follicular
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Advanced Liver Cancers
1
Interventions
pembrolizumab
44
Carboplatin
28
Cisplatin
26
Paclitaxel
24
Bevacizumab
21
human papillomavirus vaccine, L1 type 16, 18
16
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
14
atezolizumab
11
Papillomavirus Vaccines
11
Nivolumab
10
tisotumab vedotin
8
Vaccines, Synthetic
8
Gemcitabine
8
Colposcopy
8
Topotecan
7
fludarabine
6
Vaccines
6
Injections
6
Cyclophosphamide
6
spartalizumab
5
balstilimab
5
Pemetrexed
5
Irinotecan
5
Fulvestrant
5
Docetaxel
5
zimberelimab
4
durvalumab
4
Vinorelbine
4
Ipilimumab
4
Interleukin-2
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Uterine Cervical Neoplasms
×
Tiragolumab
×
Clear all
NCT04300647
2026-03-12
SKYSCRAPER-04
Hoffmann-La Roche
Phase 2
Completed
172 enrolled
27 charts